NYSEAMERICAN:PLXProtalix Biotherapeutics Stock Price, Forecast & News

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Protalix Biotherapeutics in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Protalix Biotherapeutics.

Protalix Biotherapeutics is scheduled to release its next quarterly earnings announcement on Monday, June 1st 2020. View our earnings forecast for Protalix Biotherapeutics.

Protalix Biotherapeutics will be holding an earnings conference call on Monday, June 1st at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

Protalix Biotherapeutics Inc (NYSEAMERICAN:PLX) posted its quarterly earnings data on Thursday, March, 12th. The company reported $0.02 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.25) by $0.27. During the same period last year, the firm posted ($0.37) EPS. View Protalix Biotherapeutics' earnings history.

Protalix Biotherapeutics's stock reverse split on the morning of Friday, December 20th 2019. The 1-10 reverse split was announced on Monday, December 9th 2019. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, December 19th 2019. An investor that had 100 shares of Protalix Biotherapeutics stock prior to the reverse split would have 10 shares after the split.

News coverage about PLX stock has been trending extremely negative recently, InfoTrie Sentiment reports. InfoTrie ranks the sentiment of news coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Protalix Biotherapeutics earned a media sentiment score of -5.0 on InfoTrie's scale. They also gave headlines about the company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the stock's share price in the next few days. View the latest news aboutProtalix Biotherapeutics.

Protalix Biotherapeutics saw a increase in short interest in May. As of May 15th, there was short interest totaling 1,260,000 shares, an increase of 13.5% from the April 30th total of 1,110,000 shares. Based on an average daily volume of 179,500 shares, the short-interest ratio is presently 7.0 days. Currently, 11.2% of the shares of the company are short sold. View Protalix Biotherapeutics' Current Options Chain.

Some companies that are related to Protalix Biotherapeutics include Antibe Therapeutics (ATE), IMV (IMV), Ergomed (ERGO), Rafael (RFL), Pfenex (PFNX), OncoCyte (OCX), Neuren Pharmaceuticals (NEU), Faron Pharmaceuticals Oy (FARN), Helix Biopharma (HBP), Horizon Discovery Group (HZD), BiomX (PHGE), OncoCyte (OCX), Resverlogix (RVX), Tiziana Life Sciences (TILS) and Orgenesis (ORGS). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Protalix Biotherapeutics investors own include Brainstorm Cell Therapeutics (BCLI), Pluristem Therapeutics (PSTI), Crispr Therapeutics (CRSP), Agile Therapeutics (AGRX), Sangamo Therapeutics (SGMO), Anavex Life Sciences (AVXL), VBI Vaccines (VBIV), Amarin (AMRN), BIOLINERX LTD/S (BLRX) and Nabriva Therapeutics (NBRV).

Protalix Biotherapeutics trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "PLX."

Protalix Biotherapeutics' stock is owned by a number of retail and institutional investors. Top institutional investors include Jane Street Group LLC (0.34%). View institutional ownership trends for Protalix Biotherapeutics.

PLX stock was acquired by a variety of institutional investors in the last quarter, including Jane Street Group LLC. View insider buying and selling activity for Protalix Biotherapeutics.

Shares of PLX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of PLX stock can currently be purchased for approximately $3.34.

Protalix Biotherapeutics has a market capitalization of $108.36 million. Protalix Biotherapeutics employs 184 workers across the globe.

The official website for Protalix Biotherapeutics is www.protalix.com.

Protalix Biotherapeutics' mailing address is 2 Snunit St, Science Park, Pob 455, KARMIEL, 20100, Israel. The company can be reached via phone at +972-4-9028100.